SecBot SecBot
8-K ·Filed Jul 30, 2026

VCEL

Vericel Corp
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001628280-26-050815
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of a strong beat, raised guidance, and first-ever share repurchase program signals management confidence in sustained growth. Monitor MACI biopsy/implant trends and progress on UK MHRA submission for further upside catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$47.61
T+0 close · Jul 30, 2026 · via day close
Latest settled
−10.67%
T+60 · $42.53
Vs SPY
−13.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $47.61entry
  2. T+1 · 4mo ago −3.47%α −4.17% · $45.96
  3. T+5 · 3mo ago −6.01%α −9.63% · $44.75
  4. T+20 · 3mo ago −13.51%α −17.47% · $41.18
  5. T+60 · 25d ago −10.67%α −13.13% · $42.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vericel reported Q2 2026 revenue of $77.5M (+22% YoY), beating consensus of $72.7M, and GAAP EPS of $0.04 vs -$0.01 a year ago and consensus -$0.03. The company raised full-year 2026 revenue guidance to $330-340M and authorized a $200M share repurchase program, its first ever.

Key Financial Metrics

EPS
$0.04
est −$0.03 · +233.3%
Revenue
$77.5M
est $72.7M · +6.5% · +22.5% YoY
Rating
beat
Guidance
$330M-$340M
raised
Free Cash Flow
$14.3M
Gross Margin
73%

Key Facts

  • Total revenue $77.5M, up 22% YoY, vs consensus $72.7M
  • GAAP diluted EPS $0.04 vs -$0.01 YoY and consensus -$0.03
  • Full-year 2026 revenue guidance raised to $330-340M from $326-336M
  • Board authorized $200M share repurchase program
  • MACI revenue grew 23% to $65.5M; Burn Care revenue grew 22% to $12.0M
  • Net income of $2.2M vs net loss of $0.6M in Q2 2025
  • Free cash flow of $14.3M in Q2; $29.4M in H1 2026
  • Cash and investments of $227M, no debt

Financial Impact

Revenue beat by ~$4.8M (6.5%) vs consensus; EPS beat by $0.07 vs consensus; guidance raised by $4M at midpoint; $200M buyback represents ~8% of market cap

revenueepsguidancefree cash flowshare repurchase

Risk Factors

  • Execution risk on scaling manufacturing at new Burlington facility
  • Regulatory and commercial uncertainty for MACI UK approval
  • Potential impact of healthcare policy changes on reimbursement

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-050815
Document: vcel-20260730.htm0001628280-26-050815
Document: 0001628280-26-050815-index-headers.html0001628280-26-050815
Document: 0001628280-26-050815-index.html0001628280-26-050815
Document: 0001628280-26-050815.txt0001628280-26-050815
8-K Data (Synthetic)0001628280-26-050815

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026